Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer

MLA

Cheng WJ, et al. “Combined Docetaxel/Pictilisib-Loaded MPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer.” International Journal of Nanomedicine, vol. ume 17, Nov. 2022, pp. 5353–74. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.41f605d5b23c4342b63aeeef628ed45a&authtype=sso&custid=ns315887.

APA

Cheng WJ, Lin SY, Chuang KH, Chen M, Ho HO, Chen LC, Hsieh CM, & Sheu MT. (2022). Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer. International Journal of Nanomedicine, ume 17, 5353–5374.

Chicago

Cheng WJ, Lin SY, Chuang KH, Chen M, Ho HO, Chen LC, Hsieh CM, and Sheu MT. 2022. “Combined Docetaxel/Pictilisib-Loaded MPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer.” International Journal of Nanomedicine ume 17 (November): 5353–74. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.41f605d5b23c4342b63aeeef628ed45a&authtype=sso&custid=ns315887.